Compare Equinix Inc (EQIX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Equinix (EQIX) trades at $995.9, down 3.55% today, amid mixed technical signals but strong analyst support. The stock shows bullish moving averages and neutral oscillators, with key support at $1,008. Fundamentally, revenue grew to $9.22B in 2025 with a net income margin of 15.63%, though valuation ratios remain elevated with a P/E of 65.6. Recent news highlights AI-driven data center demand and a $5B-$7B annual expansion plan, positioning EQIX for growth despite recent earnings misses.

Outlook: EQIX benefits from robust AI and interconnection demand, with a consensus price target of $1,250 implying ~25% upside. Risks include high capital expenditures, debt levels rising to 47.13% of assets, and execution challenges in a competitive sector. The strong buy rating (75% of analysts) and dividend yield support a positive medium-term view, but investors should monitor capex efficiency and quarterly earnings consistency.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.